Vimarsana
Biggest News Aggregation in the World

Page 22 - Phra News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Phra. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Phra Today - Breaking & Trending Today

 - Vimarsana News

BANGKOK/TOKYO -- Top Thai retailer Central Group will pursue its own brand strategy in convenience stores after making a break with Japanese partner F

Source: nikkei.com
Thailand's Central Group goes own way after FamilyMart exit - Vimarsana News

Thailand's Central Group goes own way after FamilyMart exit

BANGKOK/TOKYO -- Top Thai retailer Central Group will pursue its own brand strategy in convenience stores after making a break with Japanese partner…

Source: biztoc.com
Intertek receives UK Approved Body Designation under Part II of the UK Medical Devices Regulations 2002 - Vimarsana News

Intertek receives UK Approved Body Designation under Part II of the UK Medical Devices Regulations 2002

Intertek, a leading total quality assurance provider to industries worldwide, is pleased to announce that Intertek Medical Notified Body UK Ltd (IMNB UK Ltd) has been designated against the UK Medical Devices Regulations 2002 (SI 2002 No 618, as amended) by the Medicines and Healthcare products Regulatory Agency (MHRA). With its designation, Intertek is permitted to conduct UKCA conformity assessments and issue UKCA certificates for a range of active non-implantable and non-active medical...

What is the taxation on rental income? - Vimarsana News

What is the taxation on rental income?

The taxability of income earned by you from let-out residential house property and the tax deductions available towards rent paid, are dealt under separate provisions, under the Indian income-tax laws.

MHRA marketing authorization granted to Amicus' Pompe disease treatment - Vimarsana News

MHRA marketing authorization granted to Amicus' Pompe disease treatment

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for Pombliti + Opfolda, a two-component therapy to treat Pompe disease.